Pancragen

Also known as: PE-6 (Glu-Asp-Pro)

Overview

Pancragen is a short synthetic peptide targeting pancreatic tissue to restore β-cell activity, reduce oxidative stress, and improve insulin/glucagon balance. It promotes protein synthesis and pancreatic repair through gene modulation.

Benefits

- Supports β-cell regeneration

- Reduces inflammation/oxidative stress

- Improves insulin sensitivity

- Aids digestion

- May help metabolic syndrome

Consider This Peptide If You Want To

- Manage blood sugar irregularities

- Support pancreatic repair and metabolism

Dosage & Administration

Dosage Guidelines

Recommended Dosage

• Amount:2 mg

• Frequency:daily

• Duration:10 days

• Rest Period:

• Time of Day:morning

• Ingestion:oral

For oral administration, take before meals. Courses may be repeated after 4-6 months based on clinical assessment. Regular monitoring of blood glucose is recommended to evaluate efficacy.

Administration Routes:SubcutaneousOral

Research Findings on Dosage:

Subcutaneous Injection

• Commonly Reported Dosage: 2 mg

• Duration: 30 days, 2 months off, 2-3x per year

Oral Administration

• Commonly Reported Dosage: 1--2 capsules, 1--2x/day

• Duration: 20--30 days, every 4--6 months preventively, or 2--3 months in metabolic syndrome or diabetes

Administration Notes:

◦ Administer on an empty stomach to optimize absorption and efficacy.

◦ Monitor blood glucose levels regularly to assess response.

Mechanism of Action

Mechanism of Action

How this peptide works in the body

Chromatin Remodeling and Pancreatic Gene Reactivation

Pancragen promotes chromatin decondensation in pancreatic endocrine cells, allowing increased transcription of key regulatory genes including insulin (INS), glucokinase (GCK), and PDX1. This is achieved through enhanced histone acetylation (H3K9ac, H3K27ac) and reduced repressive methylation marks (H3K27me3), facilitating β-cell regeneration and function.

Epigenetic Modulation and Insulin Axis Sensitivity

The peptide modulates the epigenetic landscape of pancreatic islets by activating histone acetyltransferases (HATs) and suppressing histone deacetylases (HDACs), increasing accessibility to genes regulating glucose sensing and insulin secretion. It may also upregulate TET enzymes, reversing aberrant promoter methylation at key loci including MAFA and PDX1.

Anti-Inflammatory Effects in Islet Microenvironment

Pancragen reduces pro-inflammatory cytokine expression (IL-1β, TNF-α, IFN-γ) by inhibiting NF-κB signaling in pancreatic stromal and immune-infiltrating cells. It downregulates inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), mitigating β-cell apoptosis and preserving islet architecture.

Oxidative Stress Reduction and β-Cell Longevity

The peptide activates Nrf2 transcription factor in β-cells, enhancing antioxidant responses including upregulation of catalase, superoxide dismutase, and peroxiredoxins. This protects against ROS-induced DNA damage, a major contributor to islet cell senescence in diabetes.

Pancreatic Enzyme Regulation and Digestive Function

In exocrine tissues, Pancragen increases the transcription of digestive enzymes like amylase and lipase while protecting acinar cells from inflammatory stress. This supports improved digestion and nutrient assimilation, especially in individuals with subclinical pancreatic insufficiency.

Consider Stacking With

- Thymalin

- Ventfort

- Endoluten

- Chonluten

- Livagen

Side Effects & Cautions

Common Side Effects

- None documented

Cautions

- Supervise in insulinoma or hypoglycemia

- Consult before combining with insulin or diabetes meds

Rare Side Effects

- Rare hypersensitivity

Research & References

Research Highlights

Khavinson et al., 2022: Reported peptide-induced upregulation of insulin gene expression and antioxidant defense in β-cells

Trofimova et al., 2013: Documented glycemic normalization and improved islet morphology in type 2 diabetes subjects

Umnov et al., 2010: Showed reduced inflammatory infiltration in pancreatic biopsies following Pancragen administration

Khavinson et al., 2004: Described Cytogen peptides' epigenetic role in endocrine tissue regeneration

References

Khavinson V, et al. "Ultrashort peptides in gene regulation of pancreatic function." Int J Mol Sci. 2022.

Trofimova SV, et al. "Peptide bioregulators in type 2 diabetes management." Russian J Gerontology. 2013.

Umnov RS, et al. "Morphological assessment of pancreatic regeneration after peptide therapy." 2010.

Khavinson VKh. "Peptide regulation of aging and endocrine function." 2004.